Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.54 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7451045 | 0.90 | KDR (0.43) | KDRAKT1 | |
| Hydrochloric Acid SCHEMBL6774861 | 0.89 | KDR (0.42) | KDRAKT1 | |
| Hydrochloric Acid SCHEMBL7558014 | 0.88 | AKT1 (0.42) | KDRAKT1 | |
| SCHEMBL5760397 | 0.88 | MEN1 (0.56) | KDRAKT1NPC1MAPK1MEN1 | |
| SCHEMBL7377861 | 0.84 | RXFP2 (0.45) | KDRAKT1 | |
| Ammonia Solution, Strong SCHEMBL7446734 | 0.83 | AKT1 (0.43) | AKT1NPC1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7455665 | 0.80 | AKT1 (0.47) | AKT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5760425 | 0.80 | KDR (0.39) | KDRAKT1MEN1KMT2A | |
| SCHEMBL6415440 | 0.79 | F10 (0.49) | AKT1NPC1MEN1KMT2ARAB9A | |
| Hydrochloric Acid SCHEMBL7443795 | 0.79 | CNR1 (0.43) | AKT1NPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KDR 1677/4885AKT1 2887/4885NPC1 2585/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KDR 1677/4885AKT1 2887/4885NPC1 2585/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | KDR 1677/4885AKT1 2887/4885NPC1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.